A Randomized, Placebo-Controlled Phase III Trial of Yeast Derived GM-CSF Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With 'No Evidence of Disease' After Complete Surgical Resection of 'Locally Advanced' and/or Stage IV Melanoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Melanoma vaccine (Primary) ; Sargramostim (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 07 Jul 2020 Biomarkers information updated
- 20 Nov 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 20 Nov 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.